Who we are

Novalix is a premier CRO, a partner dedicated to improving the critical early stages of drug discovery, combining exceptional scientific talent and exclusive technology with a comprehensive portfolio of world-class chemistry, biophysics and pharmacology capabilities.

Make a difference

Based upon the initial concept of transferring academic knowledge into valuable industrial applications, Novalix is a private company owned by its executive management, scientific founders and employees and located near Strasbourg, France.

After two decades of delivering excellent outcomes in chemistry and biophysics for our clients, Novalix has become a trusted provider of expert services to partners ranging from virtual companies to global players.

Novalix can provide a valuable extension to the in-house capabilities of our partners, from biopharmaceutical companies to venture capital firms, by forging creative alliances tailored to individual needs. Novalix has pioneered the concept and practice of insourcing in Europe, has engaged in risk-sharing collaborations with biotechnology investors, and has also formed an alliance with a major pharmaceutical company to co-develop DNA-encoded library technology.

2002

Academic spinoffs from
Strasbourg University

2008

Combining chemistry
and biophysics

2016

Cryo-EM

2020

DNA-encoded libraries

2022

Drug discovery expansion
Guy Ourisson research
campus IBRB launch

2023

Multi targets drug
discovery alliance
Galapagos

2024

Global alliance:
Bruker acquires minority
stake in Novalix

Management

We have a cohesive management team, with a blend of scientific, entrepreneurial and operational expertise. The team is passionate about the interplay between industry and science and is convinced that CROs have a growing role in the discovery of new medicines.

Stephan Jenn

President

Stephan met inspirational people from the life science and venture capital industries while attending Wharton Business School and co-founded Novalix shortly after his return to France in 2002.

Denis Zeyer

CEO (Chief Executive Officer)

After earning his PhD from Strasbourg University, Denis trained as a protein crystallographer at the Institute of Genetics and Molecular and Cellular Biology by Novalix co-founders D. Moras and J.P. Renaud.

Christophe Dubost

CFO (Chief Financial Officer)

Christophe graduated from ESSEC Business School with a venture and entrepreneurial background before joining Novalix in 2010.

Julien Marin

COO (Chief Operating Officer)

Julien earned his PhD in chemistry from Strasbourg University and a Master’s degree from HEC Paris. He completed his post-doctoral training with S. Hanessian in Montreal and joined Novalix in 2006.

Florence Donadini

CPO (Chief People Officer)

Florence is an all-round specialist in human resources. She trained at EM Business School in Strasbourg. Before joining, Florence was HR Director for a well-known manufacturer of sport equipment.

Our funders

Our partners

Our marketplaces

We are registered providers on Scientist.com and Science Exchange.